BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Core Viewpoint - BioCryst Pharmaceuticals has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics, indicating progress towards the merger [1][2]. Group 1: Merger Details - The termination of the waiting period satisfies one of the conditions for the merger, with BioCryst expecting the merger to close in the first quarter of 2026, pending other customary closing conditions [2]. - BioCryst has filed a registration statement with the SEC, which includes a preliminary proxy statement of Astria and a preliminary prospectus of BioCryst regarding the merger [5][6]. Group 2: Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases, with a commitment to improving the lives of affected individuals [3]. - The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for various rare diseases [3].